Navigation Links
New study shows why swine flu virus develops drug resistance
Date:5/29/2012

Professor Adrian Mulholland and Dr Christopher Woods from Bristol's School of Chemistry, together with colleagues in Thailand, used graphics processing units (GPUs) to simulate the molecular processes that take place when these drugs are used to treat the H1N1-2009 strain of influenza commonly known as 'swine flu'.

Their results, published today [29 May] in Biochemistry, provide new insight that could lead to the development of the next generation of antiviral treatments for flu.

H1N1-2009 is a new, highly adaptive virus derived from different gene segments of swine, avian, and human influenza. Within a few months of its appearance in early 2009, the H1N1-2009 strain caused the first flu pandemic of the 21st-century.

The antiviral drugs Relenza and Tamiflu, which target the neuraminidase (NA) enzyme, successfully treated the infection but widespread use of these drugs has led to a series of mutations in NA that reduce the drugs' effectiveness.

Clinical studies indicate that the double mutant of swine flu NA known as IRHY2 reduced the effectiveness of Relenza by 21 times and Tamiflu by 12,374 times that is, to the point where it has become an ineffective treatment.

To understand why the effectiveness of Relenza and Tamiflu is so seriously reduced by the occurrence of this mutation, the researchers performed long-timescale molecular dynamics (MD) simulations using GPUs.

Professor Mulholland said: "Our simulations showed that IRHY became resistant to Tamiflu due to the loss of key hydrogen bonds between the drug and residues in a part of the NA's structure known as the '150-loop'.

"This allowed NA to change from a closed to an open conformation. Tamiflu binds weakly with the open conformation due to poor electrostatic interactions between the drug and the active site, thus rendering the drug ineffective."

These findings suggest that drug resistance could be overcome by increasing hydrogen bond interactions between NA inhibitors and residues in the 150-loop, with the aim of maintaining the closed conformation.


'/>"/>

Contact: Philippa Walker
philippa.walker@bristol.ac.uk
University of Bristol
Source:Eurekalert

Related medicine news :

1. STeleR study: Telerehab improves functioning after stroke
2. Night Shift Might Boost Womens Breast Cancer Risk: Study
3. 1 size doesnt fit all when treating blood pressure in people with diabetes, VA/U-M study suggests
4. As Obesity Rates Rise, Cases of Kidney Stones Double: Study
5. Physical Education Is Good for Kids Grades, Study Finds
6. New prostate cancer screening guidelines face a tough sell, study suggests
7. Chemicals in PVC Flooring Can Be Absorbed Into Childrens Bodies: Study
8. First study to suggest that the immune system may protect against Alzheimers changes in humans
9. States Use Only Fraction of Tobacco Revenues to Fight Smoking, Study Finds
10. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
11. Surgical Residents Often Fatigued, Study Confirms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... spark a conversation on the current obstacles facing infection prevention and offer strategies ... deaths caused by these infections. , The print component of “Fighting Infection” ...
(Date:3/24/2017)... ... 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce ... The clinic is the group’s 7th location in San Antonio and 23rd in Texas. ... provide care from the clinic, which opened March 22, 2017. , The ...
(Date:3/24/2017)... ... 2017 , ... As the standards bearer of advanced cancer ... positions them as the go-to thought leader in all matters concerning oncology nursing. ... always-on, always-fresh news, views and advocacy engine, called ONS Voice. , The ONS ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ( ... patients for colonoscopy at the HyGIeaCare® Center that is to be located adjacent ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration ...
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 23, 2017  HealthMine surveys with 9,250 ... revealed that health plan members want help from their ... stay engaged in their health, 2) help closing gaps ... platform for health and 5) relevant, real-time guidance. Meeting ... lowering healthcare costs. A Reason ...
(Date:3/24/2017)... , March 23, 2017  Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... Financing Commitment Term Sheet (the "Definitive Financing") it ... of the Company,s stockholders, who are referred to ... a Form 8-K filed with the Securities and ...
(Date:3/24/2017)... 24, 2017 The Board of Directors of ... Report 2016 including the complete 2016 Annual Accounts with notes. ... Nordic Nanovector,s website in the section Investor Relations/Reports and presentations/Annual ... ... Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
Breaking Medicine Technology: